Business Wire

ASICS Study Shows Exercise Has the Power to Sharpen Even the Brightest Minds and Improve Mental Performance

20.1.2023 12:23:00 EET | Business Wire | Press release

Share

Today, ASICS reveals exercise can significantly improve cognitive function and advance mental performance.​ From boosting short-term memory to increasing concentration levels, exercise enhances brain power and could be the solution to helping us pass exams or excel at work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005693/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Memory sport competitor, Ben Pridmore took part in the ASICS Mind Games study (Photo: Business Wire)

In a unique experiment, ASICS invited competitive gamers from around the world, specialising in mind games such as Chess and Esports and who rely on their cognitive function, to start an exercise programme. After four months of regular exercise, their minds were significantly sharpened and they performed at an even higher competitive level.

Participants’ international gaming rankings improved by an incredible 75% proving, yet again, the close interplay between our mind and body. The mind gamers’ cognitive function was boosted on average by 10%, with problem solving abilities improving by 9%, short-term memory increasing by 12% and processing speed and alertness improving by 10%. Group confidence levels increased by 44%, concentration improved by 33% and anxiety levels plummeted by 43%. The research shows exercise can be as effective at boosting brain function as learning a second language, daily reading, playing a new musical instrument or completing a puzzle every day.i

Professor Brendon Stubbs, a renowned researcher in movement and the mind, developed and led the experiment. Each gamer followed a training programme designed by runner turned international coach, Andrew Kastor. The programme included medium impact cardio and strength training and increased the gamers exercise levels to 150 minutes a week. Professor Stubbs measured the mental improvement of the participants based on their performance in their mind games, cognitive tests and wellbeing questionnaires over the course of their four-month research period.

Commenting on the results, Professor Brendon Stubbs said: “We all know that exercise is good for our mental and physical health but the impact on cognitive functioning has been less explored. We wanted to examine the effects of exercise on people who depend on their cognitive abilities - competitive mind gamers. Our results show significant improvements in their cognitive functioning, including concentration levels and problem-solving abilities.

“Exercise stimulates cell growth in the brain and rapidly increases blood flow to the hippocampus and prefrontal cortex, mechanisms that enable us to better retain memories, process information and problem solve quickly. If exercise can significantly increase the mental performance of professional mind gamers, imagine what it could do for the rest of us. From increasing focus when revising for an exam or improving alertness before a work presentation, exercise truly can enhance brain power.”

As well as showing that exercise improved the participants cognitive function and gaming capabilities, Professor Stubbs also found that the gamers’ mental wellbeing was significantly uplifted, with average State of Mind scores improving by 31%.ii The gamers’ average state of mind score at the start of the study was a below average 58 and at the end it was a high 76iii, demonstrating the significant impact exercise can also have on your mental wellbeing.

The study’s Head Coach, Andrew Kastor, who developed the gamers’ training programmes, stated: “These results are astonishing and speak to the power of exercise. Many of the gamers couldn’t jog for longer than a minute at the start of the study, so their training programmes had to be moderate. 150 minutes a week sounds a lot but when you break it down this could be 5 sets of 30 minutes. No matter your fitness levels, the mental benefits of exercise are accessible to all.”

Inspired by the experiment, a camera crew followed four competitive gamers as they took on regular exercise to improve their rankings on the international stage. The result was a new ground-breaking documentary ‘Mind Games – The Experiment’, narrated by the internationally acclaimed actor, and mental health campaigner, Stephen Fry. Now available to stream on Prime Video, the feature length film documents the journeys of four gamers – Kassa Korley, Ryoei Hirano, Ben Pridmore and Sherry Nhan – who specialise in Chess, Mahjong, Memory and Esports as they compete in professional tournaments around the world. Watch the documentary trailer here.

Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. We have always encouraged utilising exercise for both physical and mental benefits, but this is the first time we have explored the true impact on cognitive functioning. Mind Games – The Experiment shows the power of exercise to sharpen the mind and we hope that after watching the documentary, everyone (regardless of their age, body type or fitness level) is inspired to move to help boost their brain.”

Mind Games - The Experiment is available to stream on Prime Video from 19th January 2023.

ENDS

Notes to Editors

The ASICS study ran from May – September 2022, with 77 gamers from 20 countries completing the experiment. All passed health screening questionnaires and completed consent forms before taking part.

For further information, images or to organise an interview with Professor Brendon Stubbs, Head Coach Andrew Kastor, or one of the gamers featured in the documentary, please contact Rory Cramsie at ASICSMindGames@golin.com

i Comparisons drawn from: https://journals.sagepub.com/doi/full/10.1177/09567976221092726 and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174231/ and https://www.frontiersin.org/articles/10.3389/fnagi.2021.706672/full#:~:text=Bilingualism%20has%20been%20linked%20to,cognitive%20enhancement%20in%20older%20adults

ii ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.

iii After four months the groups state of mind score increased into the top 10% globally.

Anima Sana In Corpore Sano, meaning “A Sound Mind in a Sound Body,” is an old Latin phrase from which ASICS is derived and the fundamental platform on which the brand still stands. The company was founded in 1949 by Kihachiro Onitsuka and is now a leading designer, developer and manufacturer of running shoes, as well as various sports footwear, apparel and accessories. For more information, visit www.asics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rory Cramsie
ASICSMindGames@golin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye